Statistics for First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

Total visits

views
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer 5

Total visits per month

views
November 2023 0
December 2023 0
January 2024 0
February 2024 0
March 2024 0
April 2024 5
May 2024 0

File Visits

views
Pegram2021FirstHuman-CCBYNCND.pdf 14

Top country views

views
United States 4
South Korea 1

Top city views

views
Bloomington 3
Gangnam-gu 1
Muncie 1